UBS Group
ONCR

UBS Group’s Oncorus, Inc. ONCR Stock Holding History

UBS Group’s Portfolio ONCR Stock Details ONCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-14,650
Closed -$5.04K – 10241
2023
Q1 		$5.04K Buy
+14,650
New +$5.47K ﹤0.01% 8092
2022
Q4 		– Sell
-3,604
Closed -$3K – 11481
2022
Q3 		$3K Sell
3,604
-4,412
-55% -$5.66K ﹤0.01% 9649
2022
Q2 		$10K Buy
+8,016
New +$10.9K ﹤0.01% 8063
2022
Q1 		– Sell
-3,142
Closed -$17K – 11262
2021
Q4 		$17K Buy
+3,142
New +$24.3K ﹤0.01% 8107
2021
Q3 		– Sell
-60,940
Closed -$841K – 10373
2021
Q2 		$841K Buy
60,940
+58,431
+2,329% +$902K ﹤0.01% 4326
2021
Q1 		$35K Sell
2,509
-4,712
-65% -$97.6K ﹤0.01% 6887
2020
Q4 		$233K Buy
+7,221
New +$167K ﹤0.01% 5150

Other funds holding ONCR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
YAL
Your Advocates Ltd Houston, Texas $350M AUM 21.03% 1-Year Est. Return

UBS Group's ONCR Position: Q2 2023 in Review

UBS Group sold out of Oncorus, Inc. (ONCR) in Q2 2023, closing a stake of 14,650 shares — an estimated $5.04K sold.

UBS Group first reported a position in ONCR in Q4 2020 and held it in 7 quarters. The position peaked at $841K in Q2 2021. 4 funds tracked by Wall St. Rank hold ONCR as of Q2 2023.

  • UBS Group reported no remaining Oncorus, Inc. position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 14,650 Oncorus, Inc. shares in Q2 2023, an estimated $5.04K.
  • UBS Group first reported a position in Oncorus, Inc. in Q4 2020 and held it in 7 quarters.
  • UBS Group's Oncorus, Inc. position peaked at $841K in Q2 2021.
  • 4 funds tracked by Wall St. Rank held Oncorus, Inc. as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.